CAJ | 학술논문

目的：观察恩替卡韦联合安络化纤丸治疗失代偿期、乙型肝炎肝硬化的治疗及安全性。方法随机将96例活动性乙型肝炎肝硬化患者分为治疗组和对照组，每组48例，两组均在常规，保肝利尿及支持对症基础上应用恩替卡韦0.5mg治疗，治疗组在对照组基础上联合安络化纤丸6g一日两次口服，治疗52周，观察治疗前后患者临床症状，肝功能、凝血功能、变化情况。结果在治疗12个月，治疗组与对照组alt复常率分别96.4%和76.5%。两组患者HBV-dna转阴（P＜0.05）。治疗组治疗前后肝功能、凝血功能、肝纤维化、指标改善幅度明显高于对照组。结论恩替卡韦联合化纤丸治疗活动性乙型肝炎、肝硬化能有效抑制乙型肝炎病毒复制，明显改善肝功能、改善患者生活质量，延长其生存期。
목적：관찰은체잡위연합안락화섬환치료실대상기、을형간염간경화적치료급안전성。방법수궤장96례활동성을형간염간경화환자분위치료조화대조조，매조48례，량조균재상규，보간이뇨급지지대증기출상응용은체잡위0.5mg치료，치료조재대조조기출상연합안락화섬환6g일일량차구복，치료52주，관찰치료전후환자림상증상，간공능、응혈공능、변화정황。결과재치료12개월，치료조여대조조alt복상솔분별96.4%화76.5%。량조환자HBV-dna전음（P＜0.05）。치료조치료전후간공능、응혈공능、간섬유화、지표개선폭도명현고우대조조。결론은체잡위연합화섬환치료활동성을형간염、간경화능유효억제을형간염병독복제，명현개선간공능、개선환자생활질량，연장기생존기。
Objective To observe efifcacy and safety of entecavir combined with Anluohuaxian pill in treatment of active hepatitis B cirrhosis of the liver.Methods 96 patients with active hepatitis B cirrhosis were randomly divided into treatment group and control group, each group of 48 cases. two groups patients were treated with entecavir in a dose of 0.5mg on basis of diuresis and supportive therapy. the treatment group patients orally took anluohuaxian pill 6g twice a day for 52 weeks. the clinical symptoms of patients before and after treatment, the changes of liver function and blood coagulation function were observed.Results after 12 months treatment, the treatment group alt recovery rate was 96.4%, while this rate was 76.5% in control group. two groups patients showed HBV-dna negative (P < 0.05). the liver function, blood coagulation and liver ifbrosis degree in the treatment group were improved signiifcantly higher than that in the control group.Conclusion entecavir combined with anluohuaxian pill in the treatment of hepatitis B cirrhosis can effectively inhibit the replication of hepatitis B virus, improve liver function, improve the quality of life of patients, and prolong the survival period.